Voyager Therapeutics (NASDAQ:VYGR) outlined what CEO Al Sandrock described as three “pillars of value” for the year ahead during a discussion at Oppenheimer’s 36th Annual Life Science Conference, ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.

For the uneasily offended, calm responses have a greater impact than emotional ones. Here’s how they make keeping cool look ...

Five years ago, real-time clinical decision support and documentation that writes itself would have sounded like science fiction. Today, these capabilities are shipping in production software. The gap ...

Jay Olson Oppenheimer & Co. Inc., Research Division. Hello, everyone, and welcome to Oppenheimer's 36th Annual Life Science Conference. I'm Jay Olson, one of the biotech analysts ...

Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies, today announced that it was awarded 1st place at the prestigious Innovation Exchange Award and ...

The Global Point-of-Care (POC) Diagnostics Market is projected to expand at a CAGR of 11% through 2028. Growth is being fueled by the rising burden of infectious diseases, increasing demand for rapid ...

Human pluripotent stem-cells (HPSCs)—including human embryonic stem-cells and human induced pluripotent stem-cells—are reshaping the landscape of regenerative medicine.1,2 In Parkinson's disease, ...

For too long, the promise of personalized therapies has been tantalizingly close, yet frustratingly out of reach for ...

This transition is explored in “Embodied Artificial Intelligence in Healthcare: A Systematic Review of Robotic Perception, ...

Arcus Biosciences beat FY25 EPS/revenue estimates as Casdatifan drives upside; $1.01B cash funds Phase 3 into 2H28. Click for my latest analysis of RCUS stock.